COMMUNIQUÉS West-GlobeNewswire

The Kidney Foundation of Canada highlights need for Canadians to act on kidney health
26/02/2026
Take Action This Kidney Health Month and Ahead of World Kidney Day 2026 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- As Kidney Health Month gets underway, The Kidney Foundation of Canada is calling on Canadians to take [...]
La Fondation canadienne du rein souligne la nécessité pour les Canadiens d'agir pour leur santé rénale
26/02/2026
Agissez pendant ce Mois de la santé rénale et à l'approche de la Journée mondiale du rein 2026 MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Alors que le Mois de la santé rénale débute, La Fondation canadienne du rein [...]
ZSFab Announces First Clinical Use of 20° Hyperlordotic Cervical Cages in Puerto Rico
26/02/2026
WALTHAM, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Dr. Fernando Villamil recently performed a three-level anterior cervical discectomy and fusion (ACDF) at Ashford Hospital in Puerto Rico using ZSFab’s 20° InterConnect™ [...]
Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets
26/02/2026
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a [...]
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results
26/02/2026
2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4 [...]
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
26/02/2026
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended [...]
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH- [...]
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
26/02/2026
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth [...]
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
26/02/2026
— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years — — Conference call today at 4:30 p.m. ET — BRISBANE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE [...]
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26/02/2026
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
26/02/2026
Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndrome DNL126 (ETV:SGSH) Phase 1/2 preliminary data [...]
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
26/02/2026
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or [...]
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
26/02/2026
Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% [...]
Keros Therapeutics Appoints Charles Newton to its Board of Directors
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics
26/02/2026
Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted gross profit and [...]
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
26/02/2026
– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ (axatilimab-csfr [...]
DeepHealth Achieves CE Mark for TechLive™ and Enables AWS Marketplace Deployment, Advancing Global Expansion of Multimodality Vendor-Agnostic Remote Scanning Solution
26/02/2026
SOMERVILLE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced that TechLive™, its [...]
Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook
26/02/2026
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full [...]
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
26/02/2026
NORCROSS, Ga., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today [...]

Pages